Comparison
Cagrilintide vs. Dulaglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
1415456-99-3
923950-08-7
Molecular weight
4253.7 g/mol
59670 g/mol
Half-life
168 h
110 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYGLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
5
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2